Sandoz Subsidiary Called Out for Contamination Risk

Drug Industry Daily
A A
The FDA cited Fougera Pharmaceuticals’ facility in Hicksville, New York, serving the Sandoz subsidiary a Form 483 for failing to follow procedures designed to prevent contamination of its drug products.

To View This Article:

Login

Subscribe To Drug Industry Daily